UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

UroGen Pharma Ltd.NASDAQ: URGN

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $51.49M rose 47.2% year over year, behind the +82.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 30.8% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.

Context

  • Selling, general & admin amounted to 141.3% of revenue in FY2025, up 141.3 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $244.58M (+57.7%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.49M+30.8% QoQ
Last fiscal yearDec 2025
$155.1M— YoY
LTMMar 2026
$171.62M+82.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.2%+12.6%-34.6 pp
1 year—+57.7%—
3-year CAGR+23.3%+55.5%+32.2 pp
5-year CAGR+37.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
155.1M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's LTM Mar 2026 selling, general & admin of $171.62M is the highest of the 3 companies compared; the peer median is $64.02M.
  • Its year-over-year change of +82.6% is the highest of 3, against a peer median of +21.9%.
  • Selling, general & admin amounts to 122.2% of revenue for URGN, versus a peer median of 1471.2%.
URGN Competitors Peer median
Selling, General & Admin for URGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
URGNUroGen Pharma Ltd.LTM Mar 2026$171.62M +82.6%+23.3%122.2%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$90.71M +34.9%+125.7%1471.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$37.33M +8.8%-81.3%—
Peer median (excluding URGN) $64.02M+21.9%+22.2%1471.2%

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.04M64.36M82.71M90.4M109.79M
Cost of Revenue5.16M7.65M9.36M8.88M12.45M
Gross Profit42.89M56.7M73.35M81.52M97.34M
Gross Margin89.3%88.1%88.7%90.2%88.7%
Research & Development47.64M52.91M45.61M57.15M67.11M
Selling, General & Admin082.84M93.27M0155.1M
Operating Expenses135.18M135.74M138.89M178.3M222.2M
Depreciation & Amortization831K1.82M1.71M329K2.41M
EBITDA(108.54M)(76.21M)(60.35M)(95.35M)(135.66M)
EBITDA Margin-225.9%-118.4%-73.0%-105.5%-123.6%
Operating Income(92.29M)(79.04M)(65.54M)(96.78M)(124.86M)
Operating Margin-192.1%-122.8%-79.2%-107.1%-113.7%
Interest Income365K938K2.64M8.9M5.97M
Interest Expense17.44M8.44M14.72M12.52M33.85M
Other Income / Expenses(17.08M)(28.99M)(32.79M)(27.26M)(28.55M)
Income Before Tax(109.37M)(108.03M)(98.32M)(124.04M)(153.42M)
Pre-Tax Margin-227.7%-167.9%-118.9%-137.2%-139.7%
Income Tax Expense1.45M1.76M3.92M2.83M78K
Net Income(110.82M)(109.78M)(102.24M)(126.87M)(153.49M)
Net Margin-230.7%-170.6%-123.6%-140.4%-139.8%
EPS (Basic)(4.96)(4.79)(3.55)(2.96)(3.19)
EPS (Diluted)(4.96)(4.79)(3.55)(2.96)(3.19)
Weighted Avg Shares22.35M22.81M28.83M42.88M48.12M
Weighted Avg Shares (Diluted)22.35M22.81M28.83M42.88M48.12M

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.